Tag:
ExonHit Therapeutics
Latest Headlines
Latest Headlines
ExonHit buys RedPath in $32M diagnostics play
France's ExonHit Therapeutics has established a new beachhead in the U.S. molecular diagnostics market with its newly announced deal to buy Pittsburgh-based RedPath Integrated Pathology for $22.5
ExonHit, bioMerieux nix colon cancer program
French drugmakers ExonHit Therapeutics and bioMérieux have decided against pursuing their collaboration in colon cancer after a recent review of data by a scientific committee. Both companies
BMS inks $413M pain pact with Allergan
A day after getting a new CEO, Bristol-Myers Squibb has paid $40 million upfront and promised up to $373 million more in milestones to license Allergan's experimental therapy for neuropathic pain.
